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Coronary heart disease is the leading cause of death worldwide. Infarct size can be 
limited by interventions used after the ischemic event like the use of thrombolytic therapy or 
primary percutaneous coronary intervention. Paradoxically, however, the return of blood flow 
can also result in additional cardiac damage and complications, referred to as reperfusion injury. 
It has been shown that reperfusion injuries can be decreased by postconditioning- rapid 
intermittent interruptions of blood flow in the early phase of reperfusion, or post-treatment using 
various drug therapies which applied during reperfusion can reduce infarct size. H2S, a gas that is 
synthesized in mammalian tissue, has been reported to be cardioprotective during ischemia-
reperfusion injury. The means by which H2S is cardioprotective during I/R are believed to be: the 
opening of the sarcolemmal KATP channel, the generation of antiapoptotic effects inside the cells 
as well as a direct antioxidant effect.  
Low levels of reactive oxygen species (ROS) are constantly produce within cells and play 
important roles in cell signaling, cellular homeostasis, differentiation and apoptosis. However an 
excessive increase in the level of ROS can be harmful and has been proposed to play crucial 
roles or contribute in the development of various diseases. 
The aim of our study was to investigate the effects of H2S in an acute ischemia-
reperfusion model and to determine whether exogenous administration of H2S in both healthy 
rats and rats exposed to experimental models of cardiac disease influenced the production of 
ROS. In order to do this we established a method trough which we were able to measure the 
presence of ROS in heart tissue samples harvested from normal rats and rats with heart 















ACE = angiotensin- converting enzyme 
Ang II = angiotensin II 
ATP = adenosine triphosphate 
BH-4 = tetrahydrobiopterin 
CAT = cysteine aminotransferase 
CBS = cystathionine β synthetase  
CF = coronary flow 
-COOH = carboxylic 
CSE = cystathionine γ lyase  
DHE = dihydroethidium 
DMSO = dimethyl sulfoxide 
dP/dt = first derivative of pressure over time 
eNOS = endothelial nitric oxide synthase 
ERK = extracellular-signal regulated kinase 
H2O2 = hydrogen peroxide 
H2S = hydrogen sulphide 
HIT = intensity interval training   
HO = hydroxyl radical 
HR = heart rate  
I/R = ischemia/reperfusion 
IU = international units 
i.p. = intraperitoneal  
JNK = c–jun NH
2
-terminal kinase  
KHB = Krebs-Henseleits buffer  
LV = left ventricle  
LVDP = left ventricular developed pressure 
PCI = percutaneous coronary intervention  
MAPK = mitogen-activated protein kinase 
METC = mitochondrial electron transport 
chain 
MIT = moderate intensity interval training  
MST = mercaptopyruvate sulfurtransferase 
mPTP = mitochondrial permeability 
transition pore  
NADPH = nicotinamide adenine 
dinucleotide phosphate-oxidase 
NaHS = sodium hydrosulfide  
NO = nitric oxide  
O2¯   = superoxide anion 
PKC = protein kinase C  
RAS = renin-angiotensin system  
RISK = reperfusion injury salvage kinase  
ROS = reactive oxygen species  
SEM = standard error of the mean 
TAC = transaortic constriction 
UA = uric acid 
XO = xanthine oxidase  
XOR = oxidoreductase 
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Coronary heart disease is the leading cause of death worldwide. Of the 16.7 million deaths from 
cardiovascular diseases every year, 7.2 million are due to ischemic heart disease. [1] 
In early 1980s two modes of therapy were introduced to restore blood flow in occluded artery. 
One involved pharmacologic dissolution of blood clots with a thrombolytic agent and the other 
involved mechanical disruption of clots with so-called primary balloon angioplasty. [2]  
Early and successful myocardial reperfusion with the use of thrombolytic therapy or primary 
percutaneous coronary intervention (PCI) is still the most effective strategy for reducing the size 
of a myocardial infarct and improving the clinical outcome. Paradoxically, however, the return of 
blood flow can also result in additional cardiac damage and complications, referred to as 
reperfusion injury. 
According to Yellon et al. there are four types of cardiac injury during myocardial reperfusion: 
myocardial stunning, the no-reflow phenomenon, reperfusion arrhythmias and lethal reperfusion 
injury. Studies in animal models of acute myocardial infarction suggest that lethal reperfusion 
injury could account for up to 50 % of the final size of a myocardial infarct in a standardized 
situation with ischemia- reperfusion, and a number of strategies have been shown to ameliorate 
lethal reperfusion injury [3].  
Reperfusion injury of the myocardium seems to be a complex phenomenon involving several 
independent factors such as: intracellular calcium overload, inflammation, rapid restoration of 
physiologic pH and the generation of reactive oxygen species. All of this contributes to the 
opening of the mitochondrial permeability transition pore (mPTP) and the induction of 
cardiomyocyte hypercontracture. Trough the opening of the mPTP, the oxidative 
phosphorylation uncouples and the mitochondrial swells leading to cardiomyocyte death.  
Potential causes of injury that developed during reperfusion are difficult to analyze, as these 
must be clearly differentiated from ischemic causes [4]. The most accurate means of showing the 
existence of lethal reperfusion injury is to show that the size of a myocardial infarct can be 




Postconditioning was first described by Zhao and colleagues in dogs [6], and it was defined as 
rapid intermittent interruptions of blood flow in the early phase of reperfusion. 
The postconditioning algorithm was 30s of reperfusion followed by 30s of coronary occlusion, 
repeated for three cycles at the onset of reperfusion [7]. 
Since then the term “postconditioning” was also used to describe various drug therapies which 
applied during reperfusion can reduce infarct size. This may also be referred as “post-treatment”. 
The mechanism of ischemic postconditioning is not fully understood, but the procedure has been 
shown to target important mediators of lethal reperfusion injury. It seems that ischemic 
postconditioning reduces oxidative stress, opens the KATP channels , improves endothelial 
function, reduces neutrophil accumulation, decreases intracellular Ca2+ overload, delays the 
restoration of neutral pH, activates the RISK pathway and inhibits the opening of the 
mitochondrial permeability transition pore through this protecting against lethal reperfusion 
injury [3]. 
Zhao ZQ and Vinten-Johansen proposed than when considering postconditioning it is useful to 
use the concept of triggers, mediators and end effectors such as they are used when talking about 
preconditioning as similar pathways and signals may be involved in both of the processes [7].  
Trigger mechanisms that were shown to play a role in postconditioning are: generation of 
reactive oxygen species (ROS), induction of pro-inflammatory cytokines, expression of tissue 
factor, endogenous adenosine, endogenous opioids and nitric oxide (NO). Mediators that might 
be involved in postconditioning are: the activation of intracellular protein kinase C and of other 
survival and death kinases, the reduction in intracellular Ca²+ overload and the opening of KATP 
channels. The end-effectors involved in reperfusion injury seem to be the inhibition of the mPTP. 
Although postconditioning using repeated cycles of reperfusion and occlusion was the most 
investigated strategy, it seems to have different results depending on the animal model that was 
used, number of cycles and the duration of ischemia and reperfusion in each cycle [8]. 
Until now two clinical studies have been performed showing the beneficial effects of 
postconditioning on human hearts. Laskey [9] reported a study of 17 patients undergoing 
percutaneous coronary intervention for acute myocardial infarction who were randomly assigned 
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to standard reperfusion therapy or a postconditioning protocol. The postconditioning protocol 
consisted of two 90 s balloon reinflations with 3–5 min of reperfusion between them. Final ST 
segment elevation in the postconditioning group (1.60 mV) was less than in the control group 
(4.0 mV, P<0.001) and coronary flow velocity reserve was also improved.  
Staat et al. [10] reported a multi-center randomized clinical trial of 37 patients with total 
coronary artery occlusion undergoing angioplasty/stenting.  Patients were assigned to reperfusion 
with direct stenting alone (control group) or were subjected to a postconditioning protocol 
following reperfusion by stenting. The postconditioning protocol consisted of 4 cycles of 1-min 
re-inflation followed by 1min deflation of the angioplasty balloon. Infarct size (area under the 
creatine kinase curve) was significantly less, and the coronary blood flow achieved was greater 
in the postconditioned patients.  
These results encourage the development of therapeutic approaches to reduce infarct size by 
specific measures applied during the early phase of reperfusion. Many pharmacological 
strategies from different pharmacological categories have been studied, some of them having 
multiple mechanisms of action. Some of this include opioids [11], bradikinin [12], cyclosporine 
[13], Na(+)/H(+) exchange inhibitors [14,] antioxidants/free radical scavengers [15] , renin-
angiotensin system (RAS) antagonists [16], adenosine and adenosine receptor agonists [17] etc. 
 
1.2 HYDROGEN SULFIDE 
Hydrogen sulfide, the gas that is believed to be the reason for life extinction on earth 250 million 
years ago [18], is nowadays seen as an important signaling molecule with essential roles in 
human biology. 
It`s physiological actions were first proposed in 1996 by Abe and Kimura [19] who based their 
studies on earlier findings which showed that endogenous levels of H2S are produced in the rat 
brain [20]. 
H2S is synthesized in mammalian tissue through enzymatic and nonenzymatic pathways. The 
enzymes that are involved in H2S production are: Cystathionine β synthetase (CBS), 
Cystathionine γ lyase (CSE), 3 mercaptopyruvate sulfurtransferase (3 MST) and CAT (cysteine 
aminotransferase). 
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Figure 1.1 The biosynthesis of H2S in mammalian cells. CSE (Cystathionine γ lyase) and CBS (Cystathionine β synthetase)are 
cytosolic enzymes and wheres 3 MST (3 mercaptopyruvate sulfurtransferase) is both cytosolic and mytocondrial. 
 
Once synthesized, H2S can be further oxidized to thiosulfate which will be converted into sulfite 
and sulfate. H2S can also be methylated to form methanethiol and dimethyl sulfide or can act as a 




                                          
Figure 1.2. The degradation of H2S in mammalian cells (Modified after Ling Li et al. Annu. Rev. of Pharmacol. Toxicol. 2004). 
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In the adult rat H2S generation is highest in the liver and brain, followed by kidney, heart, aorta 
and small intestine [21]. 
The physiological concentration of H2S in blood and various tissues is not really known because 
different measurement techniques revealed a wide range of concentrations, but recent estimations 
have placed the human plasma concentration of H2S in the submicromolar range [22]. 
Although in most of the studies H2S has a vasodilatator effect, there are reports that contradict 
this finding [23] or show no effect on vessel wall [24]. A dual effect of this gas, depended on its 
concentration, has also been reported [25], [26]. H2S was reported to mediate vasodilatation 
trough the opening of KATP channels in the smooth muscle [25, 27, 28, 29,]. In addition, H2S was 
reported to reduce ATP levels in the cell, and by this means to mediate smooth muscle relaxation 
[30].  
H2S has been shown to inhibit ACE activity of endothelial cells and trough this mechanism have 
the potential to lower blood pressure [31]. Studies that investigated this theory revealed 
contradictory results. Some studies reported an increase in mean arterial blood pressure after the 
infusion of H2S directly into CNS [32], while others reported the opposite [28]. To support the 
result that H2S would rather decrees blood pressure is the fact that by suppressing the production 
of H2S the blood pressure increases [33]. 
H2S has been reported to be cardioprotective during ischemia-reperfusion injury. Studies suggest 
that H2S may exert preconditioning and postconditioning actions. H2S administrated before 
ischemia limits infarct-size induced by I/R in the heart in a concentration depended manner [24]. 
Post-treatment with H2S donors during reperfusion has also been shown to protect the heart 
against I/R injury [34], although some studies showed no such effect. 
The most important means by which H2S is cardioprotective during I/R is believed to be by 
opening of the sarcolemal KATP channel. The opening of the sarcKATP channel will enhance 
shortening of the cardiac action potential duration by accelerating phase 3 repolarization. This 
will inhibit calcium entry into the cell via L-type channels and prevent calcium overload during 
ischemia and early reperfusion. In addition H2S has been shown to activate PKC in the heart and 
consequently lower intracellular calcium [35].  
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There are studies that suggest that H2S has also anti-apoptotic roles in the cell during I/R. In one 
of the studies the role of the pro-apoptotic pathways p38 MAPK and JNK1/2 and administration 
of NaHS were investigated in an I/R setting [36]. The investigators found that regional 
myocardial ischemia (25 min) and reperfusion (30 min) increased the phosphorylation of         
p38MAPK and JNK1/2 and thus activates these pathways, while administration of NaHS 
significantly attenuated this increase. Another study showed that H2S induced the activation of 
ERK1/2 pathway which is believed to play a pro-survival role in the setting of ischemic 
preconditioning [37]. 
H2S has been also shown to preserve the structure and function of mitochondria and therefore 
protect against ischemic injury [38]. 
 
 
1.3 ROS AND OXIDATIVE STRESS 
While O2 is both essential for life it is also toxic trough the formation of reactive oxygen radicals 
that are able to damage cellular membranes, proteins and DNA.  When O2 accepts single 
electrons it forms reactive oxygen species (ROS) such as superoxide anion (O2¯), hydrogen 
peroxide (H2O2) and hydroxyl radical (HO). Under physiological condition ROS are produced in 
low concentration and act as a signaling molecule, while in pathological condition ROS 
contribute to cell death and are involved in the pathogenesis of several important human diseases 
such as cancer, neurological disease and heart disease. ROS are constantly produced in the cell 
and under physiological conditions the cells would increase their antioxidant defenses in order to 
counteract this production. Oxidative stress occurs when the rate of ROS production 




1.3.1 Free radicals in biology 
 
Radicals are compounds that contain a single electron, usually in an outside orbit. A free radical 
is a radical capable of independent existence [39].  Most stable molecular species have the 
electrons in their outer orbit arranged in pairs with opposite spins which make them very stable. 
Radicals are highly reactive; they initiate chain reactions by extracting an electron from 
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neighboring molecules in order to complete their own orbits. Oxygen is a biradical; it has two 
unpaired electrons in separate orbits making it a strong acceptor of electrons. Oxygen free 
radicals are formed in biology by reduction of molecular oxygen. O2 reacts slowly by accepting 
one electron in reactions that require a catalyst (such as a metal-containing enzyme) [39]. 
 
 
O2                      O2¯˙  H2O2 HO˙ + H2O H2O 
           Oxygen superoxide                  hydrogen                                    hydroxyl         




Figure 1.3 Reduction of oxygen by four single-electron steps. O2 can accept four electrons which reduces it to water. When 
O2 accepts one electron it forms the radical superoxide. If superoxide is reduced by another electron, the two-electron–
reduced form of oxygen, peroxide, is produced. This will accept two hydrogens to produce hydrogen peroxide. When 
hydrogen peroxide accepts an electron it forms hydroxyl radical (HO•) and a hydroxide anion (HO–) that, when combined 
with hydrogen, produces water. 
 
The superoxide anion although very reactive has limited lipid permeability and cannot diffuse far 
from the site of origin.  
Hydroxyl radical is probably the most powerful ROS reacting quickly with a great number of 
biomolecules, such as carbohydrates, proteins and DNA. 
Hydrogen peroxide is not strictly a radical but is classified as ROS because is an important 
product in the oxidation of O2 which can generate the hydroxyl radical. 
 
1.3.2 Sources of Reactive Oxidant Species in the cardiac tissue under physiological 
conditions 
Under basal condition the generation of ROS in the heart is low, but it can increase under 
pathological conditions.  
Under physiological conditions, the main sources of ROS in the heart are: mitochondrial 



















Figure 1.4 Main sources of ROS in the cardiomyocytes. (A) Uncoupling of mitochondrial oxidative phosphorylation. (B) The 
xanthine-oxidoreductase (XOR) system. (C) Uncoupling of NO• synthesis. (D) Activation of NAD(P)H oxidase system by 
various mediators. (Modified after Marian V. et al. Int J Biochem Cell Biol. 2007) 
 
 
Other sources of ROS include cytochrome P450 monooxygenase, cyclooxygenases, 
lipoxygenases and myeloperoxidases. 
 
1. Under physiological conditions, one of the main ROS sources is the mitochondria. During 
electron transport, approximately 2–5% of electrons escape and react with O2 resulting in the 
production of ROS [40]. 
The main sites of ROS production in the mitochondria is Complex I and Complex III. While 
complex I seem to be responsible for the O2¯ produced in the heart and lung mitochondria, 
complex III is responsible for the O2¯ produced in brain under physiological conditions [41]. 
The exactly site of ROS production in Complex I is not really known, researchers suggesting 
both FMN and iron-sulfur cluster N1 [42] as electron donors to oxygen. In addition to that it 
seems that ROS production is also correlated to many different factors such as concentrations of 
Complex I substrates and products, redox state, proton motive force and pH [43]. The ROS 
produced from Complex I seem to be released mainly in the matrix and would not escape from 
intact mitochondria while superoxide produced from Complex III is also released to the 
extramitochondrial space [44].  
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2. Another source of ROS generation is NADPH oxidase. The NOX family NADPH oxidases 
are proteins that transfer electrons across biological membranes in order to reduce oxygen to 
superoxide. The prototype, NOX2 also known as gp91phox and was first described in the 
intracellular and plasma membrane of the phagocytes in close association with another protein 
p22. Nowadays six other homologues of the phagocytes NOX2 have been found (NOX1, NOX3, 
NOX4, NOX5, DUOX1 and DUOX2) in a variety of cells such as fibroblasts, tumor cells, 
vascular smooth muscle and cardiac cells and are believed to play crucial roles in a variety of 
biological process such as cell differentiation, proliferation, survival, senescence and migration 
[45]. These seven NOX isoforms are now referred to as members of the NOX family.  
NOX 2 is the most studied of this isoforms. It consists of 6 transmembrane domains containing 
two hemes, a –COOH cytoplasmatic domain and a NH2 cytoplasmatic domain.  A number of 
cytosolic regulatory subunits are required for the activation of it, namely p67phox, p47phox, p40 
phox and the GTPase Rac2. Upon activation, these are translocated and assembled with 
gp91phox and electrons are transferred from NADPH to extracellular or phagosomal oxygen in 




Figure 1.5 Structure and components of NADH/NADPH oxidase. Left panel shows the scheme of the resting state of the 
components. NADPH oxidase-1 (Nox-1) and p22phox form the electron transfer components of the oxidase, and p47phox 
and p67phox are cytosolic components that interact with these proteins to modulate its activity. The small G protein Rac 
also serves a regulatory function. The right panel shows the activated state of NADH/NADPH oxidase induced by agonists 
such as angiotensin II, endothelin, and PDGF 






The main NOX isoforms expressed in cardiac tissue are Nox2 and Nox4. 
While Nox4 seems to be expressed mainly in the cardiomyocytes during development, Nox2 is 
the main isoform in the adult cardiomyocytes and was shown to have important roles in redox-
sensitive signaling cascades [46].  
Recent studies have shown that Nox2 is normally quiescent and is activated by various stimuli 
important in heart disease such as:  angiotensin II, endothelin and cytockines, while Nox4 has 
constitutive low-level activity [45]. Studies have reported Nox2 to be found predominately on 
the plasma membrane whereas Nox4 have been reported to be found in the perinuclear 
endoplasmic reticulum [45, 47] and in the mitochondria [48]. 
 
 
3.  Cytosolic xantine oxidoreductase (XOR) is a flavoprotein enzyme which has a catalytic role 
in purine degradation. XOR has to isoenzymes, xanthine oxidase (XO) and xanthine 
dehydrogenase (XDH). Both of them catalyse the oxidation of hypoxanthine to xanthine and 
xanthine to UA, which is the end product of purine catabolism in humans. In lower mammals, 
urate oxidase will metabolizes UA to allantoin, but this enzyme is inactivated in most primates. 
Under physiological conditions XOR mainly exists as XDH which uses NAD+ for electron 
transfer resulting in the formation of NADH. In contrast, XO uses O2 for electron transfer 
resulting in the formation of superoxide and hydrogen peroxide [49]. 
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                   Fig 1.6 Part of the methabolic pathway of purine nucleotide degradation. 
 
Recently it has been proposed that NOX (NOX2) ROS production can participate in oxidative 
modification of xanthine reductase leading to the formation of xanthine oxidase and thereby 
promoting further ROS production.  
 
4. Endothelial NOS (eNOS) is a cytocrome P450 reductase-like enzyme that catalyses flavin-
mediated electron transport from the electron donor NADPH to a prosthetic heme group. This 
enzyme requires tetrahydrobiopterin (BH-4) bound near this heme group to transfer electrons to 
guanidine nitrogen of L-arginine to form nitric oxide (NO). 
Cardiomyocytes express both neuronal NOS (nNOS) and endothelial NOS (eNOS) which 
catalyze the production of nitric oxide (NO) from L-arginine. When deprived of their critical 
cofactor tetrahydrobiopterin or their substrate L-arginine, this will rather produce ROS instead of 





Fig 1.7 “Uncoupling” of nitric oxide (NO) synthesis (Modified after Zvonimir S. Am J Physiol Heart Circ Physiol. 2001) 
 
While low levels of oxygen radicals are constantly produce in cells and play important roles in 
cell signaling, cellular homeostasis, differentiation and apoptosis, high levels of ROS are harmful 
and play crucial roles in the development or contribution of various disease. 
 
1.3.3 Defense against ROS toxicity 
Because utilization of O2 can lead to the formation of toxic compounds, organisms have 
developed antioxidant defenses in order to detoxify ROS. 
Our defense against oxygen toxicity is: antioxidant defense enzymes, dietary and endogenous 
antioxidants, cellular compartmentation and repair of damaged cellular compounds. 
The antioxidant enzymes react with ROS to convert them into nontoxic compounds. 
Dietary antioxidants such as vitamin E and flavonoids and endogenous antioxidants like urate 
can terminate free radical chain reactions. Defense trough compartmentation means that the site 
where usually ROS are produced is separated from the rest of the cell. For example many of the 
enzymes that produce hydrogen peroxide are in the peroxisomes with a high content of 
antioxidant enzymes.  
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1.3.4. ROS and cardiovascular disease 
1.3.4.1 Cardiac hypertrophy 
Cardiac hypertrophy can broadly be divided into pathological or physiological hypertrophy. The 
heart responds to chronic pressure or volume overload by a significant increase in 
cardiomyocytes size which contributes to increased chamber mass and wall thickness. Studies 
have demonstrated that physiological and pathological hypertrophies have distinct structural and 
molecular bases. 
Although the stimuli and signaling pathways involved in the induction of pathological and 
physiological cardiac hypertrophy are different [51] these pathways may sometimes overlap. The 
physiological stimuli like exercise and pregnancy lead to the production of IGF I [52] which will 
activate the IGF1-PI3K (p110α)-Akt pathway. In contrast pathological stimuli will rather lead to 
increased  levels of Ang II, catecholamines and ET-1 which in turn will stimulate PI3K(p110γ), 
mitogen activated protein kinases (MAPKs), protein kinase C and calcineurin pathways.  
The structural and molecular profile of physiological and pathological cardiac hypertrophy is 
also distinct [51]. Whereas physiological hypertrophy is characterized by normal organization of 
cardiac structure and normal or enhanced cardiac function, pathological hypertrophy is 
associated with fibrosis, cell death and cardiac dysfunction. 
Studies have shown that ROS can modulate many signaling pathways known to be involved in 
cardiomyocyte hypertrophy, such as ERK1/2, JNK, p38MAPK, Akt, PKCs, and NF-κB [53]. 
The main source of ROS production in cardiac hypertrophy seems to be NADPH oxidases [54]. 
The role of various different NOX isoforms in cardiac hypertrophy depends on the stimulus. 
NOX2 seems to be involved in Angiotensin II-dependent cardiac hypertrophy [55]. On the other 
hand pressure overload-induced cardiac hypertrophy does not require NOX2, but might possibly 
involve NOX4 [56]. 
Another source of ROS in cardiac hypertrophy seems to be the uncoupled nitric oxide synthase 
[57]. A recent study proposed that the first production site of ROS in Ang II mediated 
hypertrophy is NADPH oxidase, but these ROS will increase mitochondrial ROS production, in 





1.3.4.2 Ischemia – reperfusion injury 
Lethal reperfusion injury of the myocardium seems to be a complex phenomenon involving 
several independent factors such as: intracellular Ca2+ overload, inflammation, mitochondrial 
damage, altered NO production with an altered vascular reactivity and the formation of oxygen 
radicals. It seems that the free radical formation theory is of special importance because ROS can 
be a potential trigger for most of the other events that take place during reperfusion [59]. 
A number of mechanisms have been proposed to cause oxygen radical generation in reperfused 
myocardium. These include: the enzyme xanthine oxidase, mitochondrial oxidation, activation of 
NADPH oxidase, uncoupled NO synthase, cyclooxygenase and lipoxygenase. 
It has long been demonstrated that an important source of ROS production in reperfusion is the 
enzyme xanthine oxidase. 
As explained previously XOR has to isoenzymes, xanthine oxidase (XO) and xanthine 
dehydrogenase (XDH). In healthy tissue XDH is the predominant form. XDH uses NAD as the 
electron acceptor for the oxidation of hypoxantine to xanthine. Studied showed that in the 
ischemic tissue the XO is the predominant form [60]. This may be as a result of increased 
cytosolic calcium which will activate Ca2+ - dependent proteases which convert the 
dehydrogenase form to oxidase form by proteolysis. XO reacts with molecular oxygen and forms 
superoxide and hydrogen peroxide. 
It seems that during ischemia the substrates, hypoxantine and xanthine accumulate because of an 
increased ATP degradation. This in addition to the high concentration of XO and the return of 
oxygen during reperfusion will lead to the formation of superoxide and hydrogen peroxide. 
Despite numerous studies that support this theory, there have been also negative reports so that 
the role of XOR in I/R injury remains controversial [61]. Importantly, no treatment attempts have 




Fig 1.8 Ischemia-reperfusion injury hypothesis (Modified after Pacher et al. Pharmacol Rev. 2006) 
 
 
Mitochondria seem to be another important source of ROS during reperfusion injury.  Although 
scientists are still debating the exact source of ROS production in the mitochondrial electron 
transport chain (METC) (se previous paragraphs) and whereas the most ROS production occurs 
during ischemia, or during reperfusion,  there is a general acceptance that ischemia and 
reperfusion can result in significant mitochondrial dysfunction in electron flow and ROS 
generation. Since ROS are highly reactive and short lived species, and it is believed that their 
effect should be greatest in immediate vicinity surrounding their place of production it is possible 
that mitochondrial membrane constituents, including the complexes of the respiratory chain and 
phospholipids constituents, could be the major target of ROS attack [62]. 
 
In addition to faulty generation of ROS from METC another factor that contributes to 
mitochondrial dysfunction and further generation of ROS seems to be the mitochondrial 
permeability transition pore (PTP) opening [62]. 
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PTP is a membrane protein complex located in the inner mitochondrial membrane. 
During ischemia a decreased in O2 supply results in a decreased ATP generation. If the levels of 
ATP decrease to the level that the Na+/K+-ATPase is affected,  the levels of intracellular Na+ 
will increase, leading to cellular swelling, and increased intracellular Ca2+ levels. The decrease 
in ATP and increase in Ca2+ seems to open the mitochondrial PTP resulting in further inhibition 
of the oxidative phosphorylation.  In addition, long-lasting PTP opening leads to matrix swelling 
and disruption of the outer mitochondrial membrane. The last, causes release of proapoptotic 
molecules, leading to cell death via both caspase-dependent and caspase-independent 
mechanisms [63]. 
 
Other enzymatic systems that might play a role in the production of ROS during ischemia- 
reperfusion injury are NADPH oxidase, uncoupled NOS, COX and lipoxygenase. 
The role of NADPH oxidases in IR is still controversial. Although some studies are reporting 
results that may be in favor of a role of NADPH in IR, other studies found no such function.  
NOX2 is present in human cardiomyocytes and is upregulated after myocardial infarction [64]. 
Coronary arteries from patients with coronary heart disease show increased expression of NOX2 
and increased ROS generation [65]. A recent study that included patients with chronic 
granulomatous disease (CGD) showed that in these patients brachial artery endothelial function 
were preserved after IR, in contrast with healthy individuals [66]. Patients with CGD have 
mutations in genes coding for NADPH oxidase subunits that cause almost complete disruption in 
oxidase activity in neutrophils. 
On the other hand in mouse models deficient in NOX2 and p47phox there is no decrease in 
infarct size compared with controls [67]. 
Uncoupled NO Synthase has also been indicated as a source of ROS in ischemia-reperfusion 
injury. Uncoupling of eNOS contribute to ROS generation when deficient of L-arginine or BH-4. 
BH-4 may be oxidized by post-ischemic oxidants and though it`s level decreased [59]. 
The product of reaction between NO and superoxide generated by uncoupled NOS can oxidize 
BH-4 which may lead to further eNOS uncoupling. 
ROS generated during ischemia-reperfusion mediates signaling cascades that lead to apoptosis. 
Although cardiomyocytes express defense mechanisms against ROS, this antioxidant defenses 
are overwhelmed after ischemia and reperfusion. A large number of preclinical studies have 
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shown that free radical scavengers or antioxidants have favorable effect on reperfusion injury by 
reducing myocardial infarct size, although the reproducibility of these studies is low. When the 
end point was myocardial function and stunning of the myocardium, antioxidant have been 
shown to be protective in a large number of studies. This studies used a short period of total 
ischemia (10-20 minutes), suggesting that ROS produced in the first minutes of reperfusion are 
involved in myocardial stunning in a situation not involving cell death [68]. 
Clinical studies have failed to show improved outcome after administration of various 




1) To investigate the effects of H2S in an acute ischemia-reperfusion model 
2) To develop and establish a laboratory technique in order to measure ROS presence in the 
heart, in different cardiac-disease models 
3) To determine whether exogenous administration of H2S in healthy rats and different models 

















3. MATERIALS AND METHODS 
 
3.1. H2S ADMINISTRATION IN AN ACUTE ISCHEMIA-REPERFUSION MODEL 
To test the effect of H2S in an acute heart disease model, we used the Langendorff retrograde 
perfusion technique where hearts were perfused with Krebs-Henseleits perfusion buffer (KHB)  
subjected to 30 minutes of ischemia and reperfused with or without H2S added to the Krebs-
Henseleits perfusion buffer  (Fig.3). Sodium hydrosulfide (NaHS) was purchased from Sigma 
Chemical. The end point of this substudy was infarct size. 
 
Animals 
Female Wistar rats weighing 185–210 g were used. Rats were anesthetized and anticoagulated 
with a mixture of sodium pentobarbital (100 mg/kg) and 300 IU heparin sodium i.p.  
The study conforms to the Guidelines on Accommodation and Care of Laboratory Animals (by 
the European Convention for the protection of vertebrate animals) and was approved by the 
Norwegian Committee on Ethics in Animal Experimentation. 
 
Perfusion technique 
Hearts were rapidly removed from the animal and after a brief stay in ice-cold perfusion medium 
they were cannulated by the aorta and retrograde perfusion (80 mmHg) in a standard 
Langendorff retrograde perfusion system was initiated. The perfusion medium (Krebs-Henseleits 
buffer (KHB)) contained (mM): NaCl 118.5; NaCO3 24.8; d-Glucose 11;  KCl 4.7;  MgSO4 · 
7H2O 1.2;  KH2PO4 1.2;  CaCl2 · 2H2O 2.25 . The perfusate was equilibrated with 95% O2 and 
5% CO2 (temp. 37°C) to obtain a pH of 7.35-7.40 and was filtered (5 µM Millipore filter ) before 
use. A fluid filled latex balloon connected to a pressure transducer was introduced into the left 
ventricle (LV) so as to record hemodynamic parameters such as LV diastolic and systolic 
pressure, LV developed pressure, dP/dt and heart rate. The coronary flow (CF) was measured 
manually by timed collections of effluate and myocardial temperature was thermostatically 
controlled by inserting a temperature probe into the right atrium. Before the experimental 





The perfusion system consisted of two parallel lines (one for the Krebs–Henseleit buffer alone 
and one for the H2S containing buffer) and clamps that allowed for changing between the two 
perfusates according to the experimental protocol. Global no-flow ischemia was induced by 
clamping the main perfusion line. 
 
Experimental Protocol 
After a stabilization period of 25 minutes, hearts were subjected to global no-flow ischemia for 
45 minutes followed by reperfusion with KHB or 1 µM H2S solution (Fig.3). The H2S solution 
was delivered from the onset of reperfusion and continuously for a period of 15 minutes.  
 
 
Protocol        
                25 min               45 min       120 min 
CON              
PTREAT       
               Stabilization     Global Ischemia    Reperfusion 
 
 15 minutes continuously administration of NaHS (1 µM) followed by reperfusion 
 
Fig 3.1 Protocol for perfusion 
Control group (CON) (n=7), no intervention either before or after global ischemia.  Post-treated  (Ptreat) (n=11), 
NaHS (1μM) was given respectively at the onset of reperfusion for 15 minutes followed by reperfusion with K–H 






Measurement of infarct size 
At the end of the experiments all hearts were weighed and frozen overnight. The following day 
the hearts were sectioned into 2-mm-thick slices and stained using triphenyltetrazolium chloride 
(1%) in phosphate buffer (pH 7.4) at 37°C for 15 min. Non-infarcted tissue was stained red while 
necrotic tissue remained unstained. Slices were then fixed in 4% formaldehyde solution to 
enhance the contrast between stained viable tissue and unstained necrotic tissue. Slices were then 
compressed to a uniform 2 mm thickness by placing them between two glass plates separated by 

























3.2. PILOT SUDY OF DHE STAINING TECHNIQUE AND ROS QUANTIFICATION 
To measure the presence of ROS in the heart we tested a method that uses dihydroethidium 
(DHE), a fluorescent dye to detect superoxide production. Dihydroethidium or hydroethidine is a 
cell-permeable compound that has been used for the detection and imaging of ROS in several 
studies [69]. Upon entering the cells DHE interacts with O2
− to form oxyethidium which in turn 
interacts with nucleic acids to emit a bright red color detectable by fluorescent microscope. 
A pilot study was performed in order to confirm the reproducibility of this method when used in 
fresh frozen heart samples. The aim of the pilot study was also to establish a protocol suitable for 
our laboratory in order to use DHE for ROS detection in cardiac tissue harvested from in vivo 
experimental animal studies. 
3.2.1. Material and methods 
3.2.1.1. Tissue samples 
Hearts from female Wistar rats were perfused as previous described, for 45 minutes with Krebs-
Henseleit buffer. 
3.2.1.2. Freezing of the samples 
After 45 minutes of perfusion, the hearts were removed from the Langendorff system, the 
atriums and right ventricle were removed, and  left ventricle was divided into 4 pieces which 
were frozen trough ‘snap freezing’ technique in liquid nitrogen. 
Material 
• Fresh tissue  
• Container with liquid nitrogen  
• 2-methylbutane (isopentane)  
• Metal beaker   
• Marking pen  
• Aluminum foil 
• Base molds  
• O.C.T. tissue compound (Tissue-Tech) 




A drop of O.C.T. was added into bottom of a mould and the specimen was added into O.C.T. in 
the mould. The specimen was then completely covered with O.C.T., avoiding air bubbles.  
A metal beaker containing isopentane was lowered into the liquid nitrogen until opaque drops 
appeared in the isopentane and the solution becomes misty indicating that the isopentane was 
near the freezing point (−160 °C). The metal beaker was pulled out from the liquid nitrogen and 
the mould containing the tissue was plunged into the isopentane and allowed to freeze until 
O.C.T. is white. The metal beaker with the mould inside is then lowered again into the liquid 
nitrogen for 10 second then pulled out.  
The mould was taken out with forceps, covered with a marked piece of aluminum foil and stored 
into liquid nitrogen or at -70 degrees until further use.   
 
3.2.1.3.Microtomy 
A Leitz 1720 digital Cryomicrotome was used for sectioning of frozen heart samples and thus 
there was no need for parafine or plastic embedding of the samples.  
On the day of microtomy, the mould containing the tissue is taken from liquid nitrogen with 
forceps. After 15 seconds, the specimen is pressed out from the back side of the mould and is 
then placed on a layer of O.C.T. embedding medium on top of a pre-cooled cryostat chuck. More 
O.C.T. was applied around the tissue to give it extra support if necessary. The chuck was then 
placed into the metal beaker containing isopentane previously cooled in liquid nitrogen, until the 
O.C.T. becomes white in color and indicated that it was adequately frozen. Following this, the 
metal beaker containing the chuck was again immersed into liquid nitrogen for 10 seconds prior 
to being placed in the interior of the cryostat at –24°C for 30 minutes and then mounted on the 
microtome. 
The specimen was cut in 20 µm sections. The sections were mounted on glass slides (2 sections 
per glass) and 15 µl of the prepared solution of DHE was topically added on each section and 




3.2.1.4.Microscopy & Analyzing  
The sections were examined by fluorescence microscopy and images were acquired at 25X 
magnification using the Leica Application Suite program. Different filters were tested in order to 
optimize quantification of DHE florescence. Based on this, fluorescence was detected in further 
experiments using a 585-nm long-pass filter. 
In order to have good quality pictures, the setting of the camera must be manually selected via 
Leica Application Suite program. Different values for each setting (Exposure, Saturation, Gain, 
Gamma) were tested in pilot experiments and the pictures analyzed by ImageJ. The pictures that 
were taken with different settings were converted into RGB images. The RED channel was used 
and the Pixel Intensity Histogram analyzed. We were looking for a histogram that would not 
show over- or under exposure, meaning that the range of pixels will be between 0 and 255 but 













Below are some examples of pictures and their histograms. The pictures are taken from the same 
slice, with different settings. 
This histogram shows that some of the pixels have high intensity values and might be 
overexposed: 
                           
In this histogram lots of the pixels have rather low intensity values and might be underexposed:   
                     
In this histogram, the bottom and top half of the intensity values is used by only a few pixels: 
                      
As this final histogram did not show over- or underexposure in addition to a good quality of 
picture, we selected these settings for the camera for the remaining experiments: 
Exposure= 675;    Saturation=  0.65;     Gain= 0.8 ;      Gamma= 1.4  
All images were analyzed using Image J and average intensity obtained for each image. 
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3.2.1.5. DHE staining 
In order to find the right DHE concentration and to test the stability of the DHE solution, a series 
of experiments were done. 
3.2.1.5.1. DHE concentration 
Three different concentrations of DHE in DMSO diluted with PBS were tasted (10, 12.5 and    
15 µM) and the minimal concentration (12.5 µM) that was able to color the sample in order to be 
detectable by fluorescent microscope was used. For each concentration, the solution was 
prepared in a dark microtube (capacity 1.5ml) and placed in a recipient surrounded by ice. The 





3.2.1.5.2. Stability of the DHE solution 
In order to check the stability of DHE solution with time, we colored sections coming from the 
same heart with DHE solution that was prepared and left in a dark vial for 1 to 4 hours (Fig. 
3.2).The tissue sections came from the same heart so that any difference observed between the 
sections would not be due to other external factors such as age, gender, diet etc. The specimen 
was mounted into the microtome and cut in 20 µm sections. Between 2 and 4 sections were 
mounted per glass slide with a maximum time difference of 5 minutes between each glass slide. 
Thus, within 30 minutes 6 glass slides, each containing 2 to 3 sections were colored with DHE 
solution (in a dark room due to light sensitivity) and incubated in the dark, heated chamber 
(37°C). After 30 minutes incubation for each glass, the sections were examined in the 
microscope. Each glass was examined on the microscope for a maximum time period of 5 
minutes. This procedure was repeated four times for the same tissue specimen. The experiments 






There was a decrease in fluorescence intensity after 60 minutes which was followed by more 
stable values after 180 min. However, as the heart specimen was left in the microtome (at -20 
degrees) during this experiment (respectively 4 hours), we could not be sure that the decrease in 
fluorescence intensity is due to the DHE instability or due a ‘loss of ROS’ from the tissue. 


















60 min              120 min               180 min             240 min
  
Figure 3.2. DHE fluorescence intensity of sections from the same specimen when the DHE solution was used at minute 60, 







As future experiments to be included in the present thesis regarding H2S would require 
comparison of the DHE intensity between different groups, we proceeded to validate experiment 
comparing 4 different specimens at a time. The tissue sections came from the same heart so that 
any difference observed between the sections would not be due to other external factors such as 
age, gender, diet etc.  
Four  different specimens (A,B,C,D) coming from the same heart were mounted on 4 different 
cryostat chucks and left in the microtome at -20 degrees for 20 minutes before they were first 
sliced. Each of the 4 specimens was sliced with a 7 minute time difference between them (a total 
of 28 minutes for the four of them) prior to the addition of DHE as described above. The 
procedure was repeated 3 times changing the order of the specimens. The time and order of the 3 
cycles is shown in Table 3.1. 
       Time (min)             0             75              150 
       Time point            1              2               3 
      Order A, B, C, D      A, B, D, C C, B, A, D 
 
Table 3.1. Time and order of the experiments. The 4 specimens coming from the same heart are named with alphabetical 

















































Figure 3.4. DHE fluorescence intensity presented as a function of different time points in the four groups. Data are the same 





The specimens were compared using Two-Way ANOVA test. No statistical difference between 
the intensity of the DHE in the specimens at the same time point or at different time points were 
found (Fig 3.3 and 3.4). These results suggest that we can compare different groups (coming 
from different hearts) at different time points (no longer that 150 minutes after preparation of 
DHE ) and the changes in fluorescence intensity wont be due DHE instability but rather to a 
different ROS production in the tissue (if that would be the case). 
 
3.2.1.5.3. ROS stability at -20°C 
Based on the first set of experiments we were unable to conclude whether the decrease in 
fluorescence intensity was due DHE instability or that ROS levels in the tissue decreased with 
time. In order to validate the stability of ROS in the samples over time, we performed a new set 
of experiences.  Slices from one specimen were colored with DHE and analyzed using 
fluorescent microscope (day I). The specimen was then left in the microtome for 24 hours and a 
new set of slices were taken, colored and analyzed (day II). The new set of slices (day II) ware 
then colored with two types of DHE, one prepared the same day (solution II) and another 
prepared a day before (solution I).  
Results 
There was a statistically significant difference (T-test, p<0.05) in the fluorescence intensity 
between the specimens taken the first day and the ones taken after 24 hours, in both the 
specimens stained with newly prepared DHE solution or the one that was prepared the day 
before (Fig. 3.5). This demonstrates not only the loss of stability of the DHE solution with time 






























Day I Solution I                Day II Solution I           Day II Solution II
 
Figure 3.5. Comparison of DHE fluorescence intensity of specimens left in the microtome for 24 hours and colored with 
different solutions of DHE.   
 
Conclusions  
We concluded that DHE is not stable with time so when possible, groups that will be compared 
should be tasted at the same time point using the same DHE solution.  
Because DHE is light sensitive, the solution (12.5 µM) should be prepared and added on the 
tissue slices in a dark room. In our future experiments DHE solution was prepared 1 hour before 
each of the experiments and left in a dark tube surrounded by ice. The heart specimens were cut 
in 15µm or 20 µm sections and mounted on glass slides (2 to 5 sections per glass) and 15 µl of 
the prepared solution of DHE was topically added on each section and then cover-slipped. The 
sections were then incubated at 37°C in a humidified chamber for 30 minutes. Because 
sometimes the group that is colored first can have increased fluorescence intensity, every time 
we did a new experiment we changed the order of coloring the groups. The sections were 
examined by fluorescence microscopy and images were acquired at 25X magnification using the 
Leica Application Suite program. We took approximately 25-30 pictures per heart. The pictures 
were then analyzed by ImageJ. 
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3.3. ROS MEASUREMENTS IN TWO MODELS OF CARDIAC DISEASE 
To test the feasibility of the DHE staining in groups where ROS production was believed to be 
different, we measured ROS presence from heart samples taken from animals with different 
models of heart disease where an increased ROS generation has demonstrated to contribute to the 
patho-physiological development of these diseases. 
 
3.3.1. ROS measurements in hearts from diet-induced obese mice 
Heart samples were examined from diet-induced obese mice that were or were not subjected to 
high intensity interval training (HIT) or moderate intensity interval training (MIT) for 8 weeks 
following the administration of a specialized diet. These samples were compared to a control 
group that received standard chow for the entire period. 
 
3.3.2. ROS measurements in hearts from pregnant rats subjected to transthoracic 
aorta banding 
In these experiments 4 different groups were tasted:  
Tac (n=8) - Rats that were subjected to transthoracic aortic banding  
Sham (n=8) - Rats that underwent surgery without binding of the aorta 
Pregnant Tac (n=8) - Pregnant rats that were subjected to transthoracic aortic banding 









3.4. SHORT TERM ADMINISTRATION OF H2S IN LANGENDORF PERFUSED 
HEARTS 
Animals 
Female Wistar rats (n=15) weighing 185–210 g were were anesthetized with a mixture of sodium 
pentobarbital (100 mg/kg) and 300 IU heparin sodium i.p. and the hearts were rapidly excised 
and mounted in the Langendorff perfusion system. After  a stabilization period of 15 minutes, the 
hearts were perfused for 30 minutes with one of the following solution: KHB, KHB-AgII, KHB-
H2S, where KHB denotes Krebs-Henseleits buffer. 







Figure 3.6. Experimental protocol 
Control group (n=5): Hearts were perfused throughout with normal KHB  
H2S group (n=5): Hearts were perfused 15 min with KHB for stabilization and then with H2S (1µM ) 













STABILISATION 15 min     PERFUSION with ANGIOTENSIN II for 30 min 
STABILISATION 15
 
 min    PERFUSION with H2S for 30 min 
 





3.5. LONG TERM ADMINISTRATION OF H2S TO HEALTHY RATS 
In order to investigate the effects of long term administration of H2S in healthy rats, sodium 
hydrosulfide (a H2S donor) at a concentration of 50µM and 500 µM was added in the drinking 




The study conforms to the Guidelines on Accommodation and Care of Laboratory Animals (by 
the European Convention for the protection of vertebrate animals), and was approved by the 
Norwegian Committee on Ethics in Animal Experimentation. 
Female Wistar rats (Charles River, Germany)(n=18) were acclimatized for 5 days in housing 
conditions, maintained at a 21°C temperature in air filtered and light controlled (12 hours light 
cycle) room. The rats were feed standard commercial pellets and water ad libitum.  
Rats were divided into three groups: 
Control (n=6): rats that received normal drinking water. 
Low dose H2S (n=6): rats that received H2S in drinking water at a concentration of 50 µM. 










3.6. LONG TERM  ADMINISTRATION OF H2S  IN AN EXPERIMENTAL 
MODEL OF CARDIAC HYPERTROPHY  
In order to investigate the effects of long term administration of H2S in a chronic cardiac disease 
model, we used rats that were subjected to transthoracic aortic banding and developed cardiac 
hypertrophy. These rats received H2S in drinking water for 14 days (500 µM). Following this, 
echocardiography was performed and blood pressure was measured. 
The end point of this experiment was: blood pressure, heart weight and ROS production in the 
cardiac tissue as measured by DHE staining. 
Animals 
The study conforms to the Guidelines on Accommodation and Care of Laboratory Animals (by 
the European Convention for the protection of vertebrate animals), and was approved by the 
Norwegian Committee on Ethics in Animal Experimentation. 
Female Wistar rats (n=24) that weighed between 193 – 273 grams (at surgery) were randomized 
to either banding of the ascending aorta or sham surgery. After surgery rats were housed in 
separate cages and received H2S (500µM) in their drinking water for 14 days. The rats were 
divided into 4 groups:  
Tac (n=6): rats that were subjected to transthoracic aortic banding 
Sham (n=6): rats that underwent surgery without transthoracic aortic banding 
H2S Sham (n=6): rats that underwent surgery without transthoracic aortic banding and received 
Sodium hydrosulfide in drinking water  
H2S Tac (n=6): rats that were subjected to transthoracic aortic banding and received Sodium 





3.7. MEASURMENT OF HYDROGEN SULPHIDE IN PERFUSION BUFFER AND 
DRINKING WATER   
In order to measure the final concentration of H2S in the buffer we used a modification of the 
method described by W-J Cai et al [69]. Briefly 1.0 ml of buffer added to 0.125 ml 1% zinc 
acetate in tightly sealed Eppendorff tubes. The resulting precipitate was dried under 2 millibar of 
vacuum using a Speed Vac SC-210A concentrator (Thermo Scientific) followed by addition of 
0.375 ml water. Then 0.067 ml 20mM N,N-dimethyl-phenylenediamine dihydrochloride in 7.2 
M HCl was added. This was followed by addition of 0.067 ml 30mM FeCl3 in 1.2mM HCl. 
After 30 min incubation in the dark the absorbance of the resulting methylene blue solution was 
measured at 670 nm against a calibration curve of NaHS (0.1-2.5 mM) 
 
STATISTICS 
Results are given as mean ± SEM if not otherwise stated. Sigmaplot statistical software was used 













4.1. H2S ADMINISTRATION IN AN ACUTE ISCHEMIA-REPERFUSION MODEL 
LVDP, left ventricular developed pressure (mmHg); HR, heart rate (beats/min); CF, coronary 
flow (ml/min) were measured during the perfusion with H2S;  
Exclusion criteria 
Hearts were excluded from further study if they failed to produce a left ventricular systolic 
pressure greater than 60 mmHg during stabilization, or they had a coronary flow rate outside the 
range of 6-20 ml at the end of the stabilization period. Hearts that were not successfully mounted 
and perfused within the first 5 minutes following removal were also excluded. 
 
Coronary flow  




                              
                                                  




CORONARY FLOW  (ml/min)   
 CTR H2S 
15 15,0± 1,8 15,1± 0,7 
20 14,7± 1,8 14,8± 0,7 
25 14,7± 1,8 14,7± 0,7 
75 10,7± 1,9 10,0± 0,7 
80 11,3± 1,8 10,5± 0,8 
85 11,3± 1,6 10,7± 0,7 
90 11,8± 1,7  10,4± 0,8 
95 11,6± 1,9 10,5± 0,8 
100 11,3± 1,9 10,2± 0,8 
130 10,0± 1,6 9,1± 0,7 
160 8,3 ±1,5 7,9± 0,6 
190 7,2 ±1,3 7,0± 0,5 
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Fig. 4.8. Coronary flow at baseline, during ischemia, and reperfusion. 
Heart rate 





                Control 
   
               H2S    
 
15     228,3± 14,1          265,5± 15,4 
20     238,3± 16,5          262,1± 14,0 
25     240,9± 21,2          266,6± 13,9 
75     172,2± 16,7          129,9± 19,9 
80     144,5± 39,2          136,0± 26,0 
85     182,7± 39,9          196,4± 25,9 
90     188,7± 35,3          217,1± 16,9 
95     201,1± 21,3          239,7± 16,3 
100     213,4± 46,5          238,0± 17,4 
130     211,5± 28,7          223,7± 18,7 
160    185,1± 26,9          228,6± 19,0 
190 168,5± 32,9          227,8± 15,5 
 




No statistically significant differences were found in baseline heart rate values (t-test)  
There was no statistical significant difference between the groups upon reperfusion. The percent 
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Left ventricular systolic pressure 
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Left ventricular developed pressure 
The baseline values of LVDP were comparable between groups. LVDP was reduced during 
regional ischemia in both groups. At the end of reperfusion, was no statistical significant 
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Left ventricular diastolic pressure 
There ware no statistical difference in left ventricle diastolic pressure between groups, neither at 
baseline nor during reperfusion. The LV diastolic pressure increased rapidly during ischemia 
however, no functional recovery was observed in neither of the two groups during reperfusion. 
Time (min)






























Infarct size was 25.09 ±6.29 and 26.81± 6.09 in untreated hearts (controls) and H2S treated 
hearts respectively. There were no statistically significant differences in the infarct size between 





















Control                                                                       H2S
 
Fig. 4.7  Infarct size in control (n=7) and post-treated group (n=11). Infarct size is expressed as percent of the total volume. 











Photograph of heart slices. Infarct areas are visualized by tetrazolium staining. 























4.2. ROS MEASURMENTS IN TWO MODELS OF CARDIAC DISEASE 
4.2.1. ROS measurement in the hearts from diet-induced obese mice 
There was a significant increase in the presence of ROS between the control group and the diet 
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4.2.2. ROS measurements in the hearts from pregnant rats that were subjected to 
transthoracic aorta banding 
No significant statistical difference ware found between the four groups (one way ANOVA with 
post Kruskal-Wallis test). The mean fluorescence intensities normalized to sham were        
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4.3. SHORT TERM ADMINISTRATION OF H2S IN LANGENDORF PERFUSED 
HEARTS 
No significant statistical difference in the presence of ROS were found between rats that were 
perfused with KHB buffer and the ones perfused with H2S solution. However, ROS levels were 
increased in samples from rats perfused with Angiotensin II as compared to controls. 
(p<0.05)(One way Anova with Tukey´s post test) 
 
 
                         
Representative photomicrographs of dihydroethidium staining in frozen sections of the left ventricle from 
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Fig. 4.15.  ROS production measured by dihydroethidium (DHE) staining. Results are means±SEM (n=5 hearts per group) 
 
A B C 
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4.4. LONG TERM ADMINISTRATION OF H2S TO HEALTHY HEARTS 
After 7 days of H2S administration, rats were sacrificed and the left ventricle divided into 4 
pieces which were frozen as previous described. ROS measurement was performed as described 
in Materials and Methods (page 36). For each sample an average of 15 pictures were taken and 
analyzed.  ROS levels were increased in cardiac tissue from rats that received H2S in a 
concentration of 500µM as compared to controls (One way Anova followed by Holm-Sidak 
method). 
 
        
               Control                                   Low dose H2S                                High dose H2S 
In situ detection of superoxide in the control and H2S groups. Fluorescence of microscopic sections of cardiac tissue labeled 
with the oxidative dye dihydroethidium (red fluorescence when oxidized to ethidium bromide by superoxide). (A) Weak 
superoxide signals were detected in the cardiac tissue of the control rats. (B, C) More intense production of superoxide was 






























Control                        Low Dose H2S             High Dose H2S
*
  






4.5. LONG TERM  ADMINISTRATION OF H2S  IN A MODEL OF CARDIAC 
HYPERTROPHY  
Rats were assessed postoperatively for hemodynamic functions and hypertrophic responses. 
Heart weight in TAC animals was significantly higher: 0.876 ± 0.042 g compared to 0.673 ± 
0.016 g in Sham hearts. As a consequence of the banding systolic pressure in the left ventricle of 
the hearts subjected to TAC was 195.0 ±8.0 mmHg compared to 128.2±5.8 mmHg in sham. 
Heart rate was however comparable, 425.8±10.3 in TAC animals and 407.8±11.9 beats per min 
in sham animals. 
There were no signs of heart failure. No significant changes could be detected in sham heart 
treated with H2S compared to sham alone or TAC H2S treated hearts compared to TAC with 
respect to these parameters. 
After 14 days of H2S administration, rats were sacrificed and the left ventricle divided into 4 
pieces which were frozen as previous described and stored at -70 degrees. ROS measurement 
was performed as described earlier. For each sample an average of 15 pictures were taken and 
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4.6. MEASURMENT OF H2S IN PERFUSION BUFFER AND DRINKING WATER  
In order to test the stability of the H2S a method developed during the course of this thesis work 
was used. Buffer with H2S was gassed with 5% CO2 in oxygen using the same procedures as 
when performing the perfusion experiments. The concentration of hydrogen sulphide in the 
buffer decreased from the first minutes of gassing of the perfusate. After 20 minutes of gassing 
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Fig.  4.1.8 Measurement of H2S in the perfusion buffer. Hydrogen sulphide concentration decreases with time. After 20 




The concentration of hydrogen sulphide in the drinking water that the rats received was also 
measured. There was a marked decrease in concentration with time. 
 
Fig.  4.1.9 Measurement of H2S in the drinking water. Hydrogen sulphide concentration decreases with time. The first 
numbers denotes minutes (0, 10, 30) and the following ones, hours.   
There is a marked decrease in concentration at hour 21. This can be explained by the fact that the 
bottles were left overnight and when we started measuring again, we measured the concentration 








5. H2S ADMINISTRATION IN AN ACUTE ISCHEMIA-REPERFUSION MODEL 
 
Ischemic postconditioning by intermittent interruptions of blood flow in the early phase of 
reperfusion has been shown to reduce myocardial injury not only in animal studies but also in 
clinical trials [9, 10] however the application of ischemic postconditioning can be difficult to 
implement in clinical practice.  
Although a large number of patients undergo angioplasty for acute myocardial infarction, there 
are also patients that still receive thrombolysis as a treatment to induce reperfusion. Therefore 
these patients are not able to benefit from ischemic postconditioning that may be realized during 
angioplasty. 
In these cases pharmacological postconditioning would be a better option. The term 
“pharmacological” postconditioning is used to describe a diverse array of pharmacological 
agents which have been demonstrated in experimental studies to reduce myocardial infarct size 
when given during reperfusion. Agents such as inhalational anesthetics [70], nitric oxide [71], 
adenosine [72], insulin [73], erythropoietin [74] have been demonstrated to be cardioprotective 
when given at reperfusion.  
These agents have been demonstrated to activate the RISK pathway, a pathway composed of 
“reperfusion injury survival kinases” such as PI3-K and MAP kinase ERK 1/2 which will inhibit 
the mitochondrial transition permeability pore (mPTP). 
H2S is produced in the cardiovascular system from L- cysteine by the enzyme Cystathionine 
gamma-lyase. Studies have shown that H2S regulates vascular tone by opening KATP channels. 
Johansen et al. [24] have demonstrated that H2S given before, during and at the beginning of 
reperfusion is protective against I/R injury by opening of the KATP channels and the protection is 
concentration dependent. Since this discovery, there have been many studies which have tried 
different protocols of H2S administration prior to ischemia and have demonstrated a protective 
effect. Whether H2S given during reperfusion protects the heart against I/R injury has been 
investigated in a limited number of studies [34, 75].  One of the studies used regional ischemia 
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and showed that post-treatment with six episodes of a 10-s infusion of NaHS or 2 min continuous 
NaHS infusion (100 M) improved the cardiodynamic performance, and reduced myocardial 
infarct size. 
The other study used global ischemia and showed that NaHS (1µM) given at the onset of 
reperfusion in 4 cycles of 15 seconds is protective against I/R injury. In contradiction with these 
findings, Osipov et al. [20] reported that bolus treatment with NaHS at reperfusion in a porcine 
model had no infarct-limiting effect, although infusion with the donor throughout ischemia and 
reperfusion was protective. Elsey et al. also have reported no effect of NaHS (1-50µM) given 
during reperfusion in rat hearts, although these data was not published [76]. 
In the present study we used NaHS, a donor of H2S. NaHS dissociates to Na+ and HS– in 
solution and HS– associates with H+ and produces H2S. Since the concentration of 1 µM has 
been previously shown to be protective given before ischemia, we decided to try this 
concentration.  
In the present study NaHS given at the onset of reperfusion failed to limit infarct size. The reason 
for this could be related to the concentration dependent cardioprotective effect, the loss of H2S 
from the buffer or the failure of H2S to mobilize the RISK pathway or other cellular pathways 
involved in postconditioning. We measured the concentration of H2S in the perfusion buffer and 
saw a decrease in H2S concentration after just 5 minutes of perfusion with the H2S supplemented 
buffer. The concentration decreased after 20 minutes to a concentration of 0.01 µM. This is one 
tenth of the concentration that we initially had in the buffer. Given the result of this substudy we 
concluded that our results could be explained by the fact that the H2S concentration was low and 









5.1. PILOT SUDY OF DHE STAINING TECHNIQUE AND ROS 
QUANTIFICATION 
Numerous methods are available for ROS detection and they all have different downsides and 
advantages.  The ideal assay for ROS detection should be sensitive enough to ensure that 
measurements are within the linear range of the assay and well above the limits of detection, it 
should be specific for one subtype of ROS, at least in physiological/pathophysiological 
concentrations and it should be applicable to a wide variety of experimental conditions and 
comparable between these applications. [77] 
Some of the methods used to measure ROS in cardiovascular system are: Cytocrome C 
reduction, Chemiluminescence- based techniques, Electron Spin Resonance, and detection of 
intercellular superoxide with dihydroethidium.  
Dihydroethidium, a cell-permeable compound, enters the cells and interacts with O2
− to form 
oxyethidium which interacts with nucleic acids to emit a bright red color detectable by 
fluorescent microscope. 
The strengths of this method are that it can be performed with equipment commonly available in 
research departments, it can be used to detect intracellular O2
−, and the result can be correlated 
with other methods.  
Because DHE is unstable with time, it is preferable that the tissue belonging to different groups 
is compared at approximately the same time point using the same supply of DHE solution.  
For each of our experiments a new solution of DHE was prepared 1 hour before the samples 
were colored.  Because a new solution of DHE was prepared for each experiment and there was 
variability among the controls, we needed to normalize samples to the arithmetic mean of 
control.  In order to test the feasibility of the method, we measured ROS presence in different 
models of heart disease. The measurements of ROS in the diet-induced mice yielded similar 
result to other studies [78, 79] which measured ROS in obese and/or insulin resistant mice. This 




There are some downfalls that should be taken into consideration when using this technique in 
order to detect ROS. 
The settings of the camera were chosen manually based on a number of pictures taken from 
different tissue samples. These tissue samples came from hearts that were perfused with Krebs-
Henseleit buffer. If a certain intervention would increase the amount of ROS in the rat’s heart to 
a great extent, it might be overseen by the program because it would be overexposed.  
For every heart we took approximately 25 pictures and we had approximately of 5 hearts in each 
group. The large number of photos for each group would decrease the chance for statistical 
errors. Although we took a large number of pictures for each heart/group, there was some 
variability in the fluorescence intensity within the same group.  
When taking pictures from a slice, we excluded the margins (there are usually more intense than 
the rest of the slice), and the vessels (endothelial cells showed increase intensity compared with 
myocytes). Since under some conditions the vessel wall could be an important source of ROS 











5.2. SHORT TERM ADMINISTRATION OF H2S IN LANGENDORF 
PERFUSED HEARTS 
A number of studies have demonstrated the cardioprotective effect of H2S in I/R injury. It has 
been shown that this protective effect involves the KATP channel, but other mechanisms have also 
been proposed to be involved. This include: an anti-inflammatory effect by inhibiting leukocyte 
adherence to the epithelium [80], the inhibition of p38MAPK [81], mitochondrial preservation 
[82], inhibition of myocardial contractility [83] and decrease in ROS formation [84].  
It has also been suggested that H2S reduces oxidative stress through a direct mechanism, by the 
scavenging of ROS and through an indirect mechanism by the upregulating of antioxidant 
defences. Geng et al. [85] reported that exogenous administrated hydrogen sulphide protects the 
myocytes by directly scavenging oxygen-free radicals and reducing the accumulation of lipid 
peroxidations. Kimura and colleagues [86] demonstrated that H2S protects neurons from cell 
death and oxidative stress by increasing the levels of the antioxidant glutathione. 
In order to test the hypothesis that H2S reduces ROS production in the cardiovascular tissue, we 
measured ROS presence in hearts that were perfused with H2S. 
As a positive control we used hearts that were perfused with Angiotensin II. In physiological 
conditions Ang II plays an important role in regulating blood pressure and fluid homeostasis. In 
pathological conditions Ang II contributes to altered vascular tone, endothelial dysfunction, 
structural remodeling, and vascular inflammation and thus is involved in the pathogenesis of 
hypertension, atherosclerosis, cardiac hypertrophy, vasculitis, and diabetes. Growing evidence 
indicates that Ang II induces its pleiotropic vascular effects partly through generation of reactive 
oxygen species (ROS) [87] and studies have shown the involvement of Ang II in increased ROS 
production [88]. In acordance with these studies, we also have found an increased ROS 
production in the hearts that were perfused with Ang II.  
In the present substudy there were no difference between the hearts that were perfused with H2S 
and the controls. This result may suggests that exogenous H2S administrated in a Langerdoff 
perfused heart, outside a pathological condition doesn’t play a role in modulating tissue levels of 
ROS. Another explanation may come from the fact that H2S evaporates when bubbled with 
O2/CO2, resulting in a fall in its concentration in the perfusion buffer to below a level that is not 
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cardioprotective. In order to test this theory we proceeded to measure the concentration of H2S in 
the perfusion buffer and saw a marked decrease in the concentration of H2S after 20 minutes of 
perfusion. Based on this we concluded that the low concentration of H2S was the main reason for 
not achieving cardioprotection. In the present substudy we investigated if exogenous H2S 
influences the production of ROS in a Langerdorff perfused heart that had no associated 
pathology. An interesting future experiment would be to investigate the role of exogenous H2S 
administration in a Langerdoff perfusion model that has a associated pathology that would lead 
to increase formation of ROS (for example in hearts coming from diabetic rats) or to perfuse the 

















5.3. LONG TERM ADMINISTRATION OF H2S TO HEALTHY HEARTS 
Although several studies have investigated the role of H2S in rats with different cardiac 
pathologies, there are up to date no studies that investigate the role of H2S in healthy rat hearts. 
The previous substudy showed that acute exogenous H2S administration in healthy rats did not 
change ROS levels, however chronic administration of high dose NaHS (500 µM) in drinking 
water increased ROS production in cardiac tissue. A low dose of NaHS (50 µM) had no effect on 
ROS production.  
Even though H2S can be detected in blood and other tissue, there is no agreement on a good 
method that can give a precise measurement of free H2S concentration. This problem arises from 
the fact that H2S can react with a number of different species (e.g. superoxide radical, hydrogen 
peroxide, peroxynitrite, etc.) thus making the measurement of free H2S difficult.  The most used 
method relies on trapping H2S with a metal followed by acidification and reaction with a dye 
(DMPD to form methylene blue) which is then measured spectophotometrically. Through this 
method concentration of H2S of about 50 to 100 µM were reported in the rat and human plasma. 
The limitation of this method is that it measures not only free H2S but also other species such as 
hydrosulfide anion and sulfide. Some scientists consider that these concentrations are too high to 
be consistent with life, and put the plasma concentration of H2S in the submicromolar range. [22] 
When NaHS is dissolved in saline, about one-third of H2S exists as undissociated gas and the 
remaining two-thirds as HS– anion. By administrating NaHS in drinking water is hard to predict 
how much of it would be absorbed and how much the concentration of H2S in the plasma would 
be changed. Our attempt to measure plasma H2S failed to give accurate information since our 






5.4. LONG TERM  ADMINISTRATION OF H2S  IN AN EXPERIMENTAL 
MODEL OF CARDIAC HYPERTROPHY  
In this substudy we investigated the role of exogenous administration of NaHS (500µM) in a 
modelheart hypertrophy. Previous studies have suggested a role of ROS in the development of 
cardiac hypertrophy. Although this mechanism is not fully understood, it seems that ROS 
produced by NADPH oxidase are able to modulate signaling pathways known to be involved in 
cardiomyocyte hypertrophy, such as ERK1/2, JNK, p38MAPK, Akt, PKCs, and NF-κB [53]. In 
the present study we used pressure-overload induced hypertrophy by transthoracic aorta banding 
but did not find a higher production of ROS in the hearts of these rats compared with the 
controls. Compared with other studies [89, 90], our model of hypertrophy involved just 14 days 
of pressure overload by TAC. In such a short period the rats may have developed a 
compensatory hypertrophy which would have not been characterized by negative changes, such 
as an increase in ROS production, but rather positive ones. There was also no statistical 
difference between the sham, hypertrophic hearts and hearts from rats that received NaHS in 
drinking water. A reason for this result is that the NaHS in the water might have evaporated 
before the animals drank it. In order to test this hypothesis we proceed to measuring the H2S 
concentration in the water bottles and saw marked decrees in concentration with time. While we 
could see a significant difference between healthy rats that received H2S (500 µM) in drinking 
water and the control group (see RESULTS- 4.4. LONG TERM ADMINISTRATION OF H2S 
TO HEALTHY HEARTS), we could not find such a difference between Sham and H2S-Sham 
(500 µM). The difference between this to types of experiments is that in the latter the rats were 
subjected to transthoracic surgery. This could have increased the level of stress and in the same 
time these rats could have drank less water that they would normally would. These rats also 
received pain medication, which might have influenced the production and measurement of 
ROS. Another explanation that we should take into consideration is that exogenous 
administration of H2S doesn’t have a cardioprotective effect.  It has recently been proposed that a 
marked decrease in the amount of H2S will influence the cardiovascular system rather that 
increased levels of H2S. Yang et al. showed that mice lacking CSE display pronounced 
hypertension and diminished endothelium-dependent vasorelaxation [33]. An interesting 
prospective will be to use animals that are not able to produce H2S rather that trying to increase 
the level of H2S in the body. 
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CONCLUSION 
In this study we investigated the cardioprotective role of short time H2S administration in an 
acute ischemia- reperfusion model and the influence of long term administration of H2S in a 
chronic cardiac disease on ROS production. In order to do this we established a method trough 
which we are able to measure ROS presence in tissue sampled from in vivo experimental animal 
studies. Although the method is widely used in laboratories around the world, putting it into 
practice with our own equipment represented a challenge that we finally managed to overcome. 
This method represents a simple, accurate and cheep way for estimating intracellular reactive 
oxygen species and can also easily be used by other groups in our institute. 
Our attempt to investigate the proposed beneficial role of H2S in an acute ischemia-reperfusion 
model failed to yield any cardioprotection, probably because of the low concentration of H2S that 
we had in the buffer.  
To our knowledge we are the first laboratory to investigate the role of exogenous administration 
of H2S on ROS production in healthy rat hearts. We found an increase in ROS formation at a 
concentration of 500 µM in the drinking water.  Surprisingly in the cardiac hypertrophy model 
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